Literature DB >> 12653916

American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline.

André Báfica1, Fabiano Oliveira, Luiz A R Freitas, Eliane G Nascimento, Aldina Barral.   

Abstract

BACKGROUND: American cutaneous leishmaniasis is characterized by single or multiple ulcerations. Cytokines, among other factors, have been shown to influence lesion development and tumoral necrosis factor-alpha is a major cytokine implicated in pathogenesis of ulcers. OBSERVATIONS: We tested oral pentoxifylline, a known tumoral necrosis factor-alpha inhibitor, at doses of 400 mg (2-3x/day), associated to N-methylglucamine antimoniate (15 mg/kg/day) in two patients with American cutaneous leishmaniasis unresponsive to antimonial drugs. We observed a satisfactory response with quick cure of skin lesions of these patients.
CONCLUSIONS: Our results suggest that oral pentoxifylline in association to N-methylglucamine antimoniate should be consider in refractory cutaneous leishmaniasis patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12653916     DOI: 10.1046/j.1365-4362.2003.01868.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  15 in total

1.  Oral Pentoxifylline Associated with Pentavalent Antimony: A Randomized Trial for Cutaneous Leishmaniasis.

Authors:  Graça Brito; Mayra Dourado; Luiz Henrique Guimarães; Everson Meireles; Albert Schriefer; Edgar Marcelino de Carvalho; Paulo Roberto Lima Machado
Journal:  Am J Trop Med Hyg       Date:  2017-05       Impact factor: 2.345

2.  Lesion size correlates with Leishmania antigen-stimulated TNF-levels in human cutaneous leishmaniasis.

Authors:  Fabiano Oliveira; Andre Bafica; Andrea B Rosato; Cecilia B F Favali; Jackson M Costa; Virginia Cafe; Manoel Barral-Netto; Aldina Barral
Journal:  Am J Trop Med Hyg       Date:  2011-07       Impact factor: 2.345

3.  Intermediate monocytes contribute to pathologic immune response in Leishmania braziliensis infections.

Authors:  Sara Passos; Lucas P Carvalho; Rúbia S Costa; Taís M Campos; Fernanda O Novais; Andréa Magalhães; Paulo R L Machado; Daniel Beiting; David Mosser; Edgar M Carvalho; Phillip Scott
Journal:  J Infect Dis       Date:  2014-08-19       Impact factor: 5.226

4.  Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil.

Authors:  Alon Unger; Seth O'Neal; Paulo R L Machado; Luiz H Guimarães; Daniel J Morgan; Albert Schriefer; Olívia Bacellar; Marshall J Glesby; Edgar M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2009-04       Impact factor: 2.345

Review 5.  Immunoregulation in human American leishmaniasis: balancing pathology and protection.

Authors:  K J Gollob; A G Viana; W O Dutra
Journal:  Parasite Immunol       Date:  2014-08       Impact factor: 2.280

6.  The immunobiology of Leishmania braziliensis infection.

Authors:  Camila I de Oliveira; Claudia I Brodskyn
Journal:  Front Immunol       Date:  2012-06-08       Impact factor: 7.561

7.  Macrophages participate in host protection and the disease pathology associated with Leishmania braziliensis infection.

Authors:  Angela Giudice; Célia Vendrame; Caroline Bezerra; Lucas P Carvalho; Thaís Delavechia; Edgar M Carvalho; Olívia Bacellar
Journal:  BMC Infect Dis       Date:  2012-03-29       Impact factor: 3.090

8.  Protective and pathologic immune responses in human tegumentary leishmaniasis.

Authors:  Lucas P Carvalho; Sara Passos; Albert Schriefer; Edgar M Carvalho
Journal:  Front Immunol       Date:  2012-10-04       Impact factor: 7.561

9.  IL-17 mediates immunopathology in the absence of IL-10 following Leishmania major infection.

Authors:  Claudia Gonzalez-Lombana; Ciara Gimblet; Olivia Bacellar; Walker W Oliveira; Sara Passos; Lucas P Carvalho; Michael Goldschmidt; Edgar M Carvalho; Phillip Scott
Journal:  PLoS Pathog       Date:  2013-03-21       Impact factor: 6.823

10.  IL-22 Protects against Tissue Damage during Cutaneous Leishmaniasis.

Authors:  Ciara Gimblet; Michael A Loesche; Lucas Carvalho; Edgar M Carvalho; Elizabeth A Grice; David Artis; Phillip Scott
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.